CROss Alliance® appointed by Redwood Pharma AB for the management of phase II clinical study

September 2017 - CROss Alliance® is glad to communicate the official agreement signature with Redwood Pharma AB for the set-up, coordination and management of a phase II clinical study with RP101: Redwood Pharma’s leading drug candidate for the treatment of dry eye disease in post-menopausal females.

This new clinical study, to be performed with a scientifically innovative drug product (RP101), confirms once more the capabilities of CROss Alliance® group to support with professionalism and adequate flexibility large phase II PoC studies.

All details available at:

Contact us

All the “pathways” to get in touch with CROSS. Feel free to contact us for any additional information you may need, we will be glad to assist you in the shortest time possible.

Contact us